STOCKHOLM, April 6, 2021 /PRNewswire/ -- The leading
global hygiene and health company Essity is acquiring the
distribution rights to the wound care technology
Sorbact® in Australia and New
Zealand from the Australian company Bayport Brands. In 2020,
sales of Sorbact® in the region amounted to AUD
1.7m (approximately SEK 11m).
"This acquisition underlines our ambition to accelerate growth
in advanced wound care, where we showed good organic sales growth
during the second half of 2020. It is also a good fit for our
strategy to establish a stronger presence in Australia and New
Zealand, where we - in addition to our successful Medical
Solutions operations - are also in the final phase of the
acquisition of Asaleo Care," says Magnus
Groth, President and CEO of Essity.
Sorbact® is a clinically established innovation for
advanced wound care, which is manufactured and marketed by Abigo
Medical. Essity acquired 75% of Abigo Medical in February
2020.
Sorbact® is used in wound care products to prevent
and treat infections. It does this using a natural mode of action
that binds bacteria and fungi. Sorbact® does not contain
antiseptics or other toxic substances, which is positive for both
the patient and the environment.
For further information, please contact:
Per Lorentz
Vice President Corporate Communications
+46 8 788 52 51
per.lorentz@essity.com
Johan Karlsson
Vice President Investor Relations
+46 8 788 51 30
johan.ir.karlsson@essity.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/essity/r/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand,c3319753
The following files are available for download:
https://mb.cision.com/Main/15798/3319753/1397182.pdf
|
Essity acquires
distribution rights to Sorbact in Australia and New
Zealand
|
View original
content:http://www.prnewswire.com/news-releases/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand-301262606.html
SOURCE Essity